Eli Lilly and Company (NYSE:LLY) Trading Down 0.7%

Eli Lilly and Company (NYSE:LLY - Get Free Report) traded down 0.7% on Friday . The stock traded as low as $764.90 and last traded at $765.80. 510,690 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 3,042,209 shares. The stock had previously closed at $771.55.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on LLY shares. Citigroup lifted their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the company a "buy" rating in a research report on Tuesday, April 2nd. Erste Group Bank raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, April 3rd. Bank of America raised their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a "buy" rating in a research report on Friday, March 1st. Morgan Stanley upped their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an "overweight" rating in a research report on Friday, February 16th. Finally, The Goldman Sachs Group increased their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a "neutral" rating in a research note on Thursday, April 11th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $757.95.

Eli Lilly and Company Trading Down 1.5 %

The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The firm's 50 day moving average is $761.92 and its 200 day moving average is $676.24. The company has a market capitalization of $722.55 billion, a PE ratio of 113.12, a P/E/G ratio of 1.45 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion for the quarter, compared to analysts' expectations of $8.94 billion. During the same quarter in the previous year, the business posted $1.62 earnings per share. The firm's revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, equities analysts predict that Eli Lilly and Company will post 13.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.68%. The ex-dividend date is Wednesday, May 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 76.58%.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds have recently added to or reduced their stakes in the stock. Simon Quick Advisors LLC boosted its position in shares of Eli Lilly and Company by 10.5% during the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company's stock valued at $1,706,000 after buying an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $363,000. Terril Brothers Inc. boosted its position in shares of Eli Lilly and Company by 113.2% during the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company's stock valued at $471,000 after buying an additional 429 shares during the last quarter. Hartline Investment Corp boosted its position in shares of Eli Lilly and Company by 1.1% during the fourth quarter. Hartline Investment Corp now owns 21,934 shares of the company's stock valued at $12,786,000 after buying an additional 248 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its position in shares of Eli Lilly and Company by 5.2% during the fourth quarter. Commonwealth Equity Services LLC now owns 354,565 shares of the company's stock valued at $206,683,000 after buying an additional 17,461 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.